Analysts' ratings for Intellia Therapeutics (NASDAQ:NTLA) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $63.0, a high estimate of $120.00, and a low estimate of $29.00. Observing a downward trend, the current average is 8.16% lower than the prior average price target of $68.60.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Intellia Therapeutics among financial experts is...
Login or create a forever free account to read this news
Sign up/Log in